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Down-regulation of vascular GLP-1 
receptor expression in human 
subjects with obesity
Tomohiko Kimura  1, Atsushi Obata1, Masashi Shimoda1, Ikki Shimizu2,  
Gabriela da Silva Xavier3, Seizo Okauchi1, Hidenori Hirukawa1, Kenji Kohara1, 
Tomoatsu Mune1, Saeko Moriuchi1, Arudo Hiraoka4, Kentaro Tamura4, Genta Chikazawa4, 
Atsuhisa Ishida4, Hidenori Yoshitaka4, Guy A. Rutter  3, Kohei Kaku1,5 & Hideaki Kaneto1
It has been thought that incretin signaling prevents arteriosclerosis, and very recently anti-
arteriosclerotic effects through GLP-1 receptor were finally demonstrated in clinical human study. The 
purpose of this study was to investigate how vascular GLP-1 receptor expression is influenced in human 
subjects. First, we evaluated GLP-1 receptor expression in human arteries in immunostaining. Next, we 
separated the artery into the intima and media, and evaluated gene expression levels of various factors. 
We divided the subjects into obesity and non-obesity group and compared their expression levels 
between them. Finally, we evaluated which factors determine vascular GLP-1 receptor expression. 
GLP-1 receptor expression in intima and media was lower in obesity group compared to non-obesity 
group which was correlated with the alteration of TCF7L2 expression. Multiple regression analyses 
showed that BMI was an independent determining factor for GLP-1 receptor expression in the intima 
and media. Furthermore, using small interfering RNA method and TCF7L2-EGFP adenovirus, we 
showed that TCF7L2 was involved in GLP-1 receptor expression in human vascular cells. Taken together, 
vascular GLP-1 receptor and TCF7L2 expression was significantly down-regulated in human subjects 
with obesity. In addition, it is likely that TCF7L2 functions as a modulator of vascular GLP-1 receptor 
expression.
It is known that GLP-1 receptor is present not only in the pancreas but also in various tissues including the heart, 
blood vessels, central nerve, vagus nerve, stomach, intestines, visceral fat and the kidney1,2. GLP-1 signaling in 
pancreatic β-cells increases insulin secretion in a blood glucose level-dependent manner, leading to decrease of 
blood glucose levels3. At the hypothalamus, its stimulation induces loss of appetite, leading to weight loss3,4. It 
is also known that incretin signal improves vascular relaxation response through eNOS expression and activity 
in endothelial cells5. GLP-1 signaling suppresses the expression of various pro-atherosclerotic factors in vas-
cular endothelial cells induced by hyperglycemia and inflammatory cytokines (e.g. TNF-α)6,7. Moreover, it is 
known that in arteriosclerosis model mice, GLP-1 signaling increases the expression of eNOS which leads to the 
dilatation of blood vessel8. In addition, it was reported that intravenous GLP-1 receptor agonist administration 
improved flow-mediated dilatation in human subjects9. Considering from these reports, vascular GLP-1 signaling 
improves blood vessel wall abnormalities induced by various factors such as hyperglycemia and various inflam-
matory cytokines10–12. In addition, it is known that GLP-1 signaling has anti-atherosclerotic effects in vascular 
smooth muscle cells13–16. Anti-arteriosclerotic effects through GLP-1 receptor have been indicated so far only 
in basic experiments such as animal experimental model and/or cell culture system. But finally, this effect was 
also demonstrated very recently in the clinical human study. It was shown that in patients with type 2 diabe-
tes, the usage of GLP-1 receptor agonist resulted in reduction of cardiovascular-related events and/or death17. 
Accordingly, the role of GLP-1 receptor in blood vessels has attracted much attention recently.
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On the other hand, it has been reported that GLP-1 receptor expression in β-cells is decreased in the diabetic 
state18,19 and that TCF7L2 functions as a transcription factor of GLP-1 receptor at least in β-cells20. However, it 
remains unclear whether vascular GLP-1 receptor expression changes under some conditions and which factors 
could affect vascular GLP-1 receptor expression. The purpose of this study was to reveal the alteration of vascular 
GLP-1 receptor expression and the factors affecting its expression in human subjects.
Methods
Study population. The study population consisted of 40 patients who needed artery surgery and were admit-
ted to the department of cardiovascular surgery of the Sakakibara Heart Institute from October 2014 to April 2015. 
The study protocol was reviewed and accepted by the both hospital ethics committee of Sakakibara Heart Institute 
and Kawasaki Medical School (No. 1933). And the study protocol registered to UMIN-CTR (No.UMIN000024556) 
approved by International Committee of Medical Journal Editors (ICMJE). We recruited the subjects who were ≥20 
years old and agreed to participate in this study. Written informed consent to participate in this study was obtained 
from all subjects or their representatives. We excluded the subjects having some endocrine disease and/or severe 
mental disorder. Basically, we performed the recruiting of subjects who met the inclusion criteria within a study 
period. All methods were performed in accordance with the relevant guidelines and regulations.
Blood sampling and section preparation. Blood was collected as much as possible when the condi-
tion was sufficiently stable after operation. Resected disease artery was immersed in RANlater (Qiagen, Venlo, 
Netherlands) and stored until use. Excised diseased artery was mechanically separated by forceps into the intima 
and media as described previously21.
Immunostaining. The sections were embedded in paraffin. According to a previously reported method22, 
immunostaining was performed using anti-hGLP-1 receptor antibody (MAb 3F52, Novonordisk Pharma Ltd, 
Copenhagen, Denmark). The sections were heated for 15 min in a microwave for antigen retrieval, and endoge-
nous peroxidase activity was blocked by immersion in 1% (vol./vol.) H2O2 for 15 min. After washing in TBST, 
sections were blocked with 1% skimmed milk for 15 min, and then incubated with anti-hGLP-1 receptor antibody 
at room temperature for 14 h. After rinsing with TBST, an adequate amount of anti-mouse immunoglobulin-HRP 
(DAKO) was added, and the reaction was allowed to proceed at 25 °C for 30 min. After another washing in TBST, 
an adequate amount of amplification reagent (DAKO) was added, and the reaction was allowed to proceed at 
25 °C for 5 min. In order to do an immunostaining the vascular intima, isolectin GS-IB4 Alexa Fluor 594 con-
jugate (Invitrogen) was applied to the sections. After rinsing with PBST, DAPI (SIGMA-ALDRICH) was put 
for 5 min at room temperature. We performed TCF7L2 staining according to a previously reported method23. 
Antibody for anti-TCF7L2 antibody (abcam) and anti-CD34 antibody (Santa Cruz Biotechnology) was using as 
primary antibody. Then, we added a mixture of the second antibodies (Alexa Fluor 488 donkey anti-Goat IgG and 
Alexa Fluor 594 donkey anti-mouse IgG; Invitrogen).
Real-time PCR. We mechanically separated excised diseased artery into the intima and media, and evaluated 
mRNA levels of various factors in the intima and media by real time RT-PCR. We prepared primer pairs encoding 
genes related to GLP-1 receptor and arteriosclerosis-related factors, and performed real-time RT-PCR using Sybr 
Green. To quantify gene expression, the 2−ΔCT was calculated using β-actin as an internal control.
Human umbilical vein endothelial cells (HUVEC) and human aortic endothelial cells (HAEC) and 
small interfering RNA (siRNA). HUVEC and HAEC were purchased from Lonza (USA). The cells were cul-
tured in Endothelial Cell Growth Medium 2 (EGM2 BulletKit, CC3162; Lonza) in 5% CO2 at 37 °C, separately. Before 
the experiment, the cells were incubated for 24 hours or until enough amount could be secured for experiment. We 
exposed HUVEC and HAEC to siRNA directed to TCF7L2 (siTCF7L2) or scrambled siRNA as a control and cultured 
them for 24 hours. After then, real-time RT-PCR using Sybr Green and western blotting were performed.
Overexpression of TCF7L2 in HAEC using TCF7L2-EGFP adenovirus. TCF7L2-EGFP adeno-
virus was prepared as described previously24. HAEC were incubated in EGM2 until enough amount could be 
secured for experiment. We exposed HAEC to TCF7L2-EGFP adenovirus or control EGFP and cultured them for 
48 hours. After then, real-time RT-PCR with Sybr Green and western blotting were performed.
Statistical analysis. Subjects were divided into obesity (BMI ≥ 25 kg/m2) and non-obesity group (BMI < 
25 kg/m2) and comparison of the clinical parameters and various gene expression levels in the intima and media 
was performed. The results were expressed as mean ± SE. A Wilcoxon test was used to test the difference between 
obesity and non-obesity group with p < 0.05 regarded as significant. χ2 test was used for the comparison of obese- 
and non-obese subjects at the entry point and the comparison of various parameters between the presence and 
absence of various factors. To examine which factors are associated with GLP-1 receptor expression in human aorta, 
spearman’s rank correlation coefficient test was performed. Furthermore, to examine which factors independently 
determine GLP-1 receptor expression in the intima and media, we performed multiple regression analysis.
Results
Characteristics of the study subjects. The background characteristics of 40 subjects in this study were as fol-
lows: Male/female =27/13, abdominal or thoracic aortic aneurysm/aortic dissection/arteriosclerosis obliterans/other = 
12/20/6/2, diabetic/non-diabetic = 13/26, age 68.0 ± 13.4 years old, BMI 23.8 ± 4.7 kg/m2, HbA1c 6.2 ± 1.5%. BMI in 
obese (BMI ≥ 25 kg/m2, n = 16) and non-obese group (BMI < 25 kg/m2, n = 24) was 28.6 ± 2.5 kg/m2 and 20.7 ± 2.8 kg/m2, 
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respectively (p < 0.05) (Table 1). There was no significant difference in fasting plasma glucose (121.2 ± 32.2 vs 
116.6 ± 25.0 mg/dl), HbA1c (5.9 ± 0.6 vs 6.4 ± 1.9%), HDL-cholesterol (37.1 ± 10.3 vs 39.0 ± 9.0 mg/dl), LDL-
cholesterol (111.1 ± 38.1 vs 91.3 ± 33.0 mg/dl) between the obesity and non-obesity group (Table 1).
Evaluation of GLP-1 receptor and TCF7L2 expression in the aorta of human subjects in 
immunostaining: Down-regulation of GLP-1 receptor and TCF7L2 expression in obese sub-
jects. Although most of the GLP-1 receptor antibodies available now are not working very well in several 
experiments, it has been drawing attention that GLP-1 receptor antibody MAb 3F52 which was developed by 
Novonordisk Pharma has been working very well22. Therefore, in the present study, we evaluated GLP-1 expres-
sion in human aorta using this antibody. First, to examine GLP-1 receptor expression in human aorta, immu-
nostaining was performed with this excellent antibody specific for GLP-1 receptor. As shown in Fig. 1A, GLP-1 
receptor expression in the vascular intima of human was confirmed as observed in other animals22. Furthermore, 
the expression of GLP-1 receptor in obese subjects (middle panels) was much lower compared to non-obese sub-
jects (upper panels). In order to examine the quality of GLP-1 receptor antibody and to show that such staining 
is not non-specific, we performed immunostaining in the same way without this antibody. As shown in lower 
panels, without adding this GLP-1 receptor antibody, there was no staining at all. Similarly, to examine TCF7L2 
expression in human aorta, immunostaining was performed with antibody for TCF7L2. As shown in Fig. 1B, the 
expression of TCF7L223 in the intima and media was clearly lower in obese subjects (lower panel) compared to 
non-obese subjects (upper panel).
Down-regulation of GLP-1 receptor and TCF7L2 mRNA expression both in the intima and 
media of arteries in obese human subjects. Since we obtained the findings suggesting that GLP-1 
receptor protein expression in obese subjects is lower compared to that in non-obese subjects, we mechanically 
separated the excised diseased artery into the intima and media and quantitatively evaluated various gene expres-
sion levels in the intima in the obesity and non-obesity group. As shown in Fig. 2A, GLP-1 receptor and TCF7L2 
mRNA levels in the intima were significantly lower in obesity group compared with that in non-obesity group 
(p < 0.01 and p = 0.03, respectively), which was consistent with the immunostaining results. In contrast, mRNA 
level of E-selectin which is involved in the adhesion of leukocytes and vascular endothelial cells was significantly 
higher in obesity group compared to non-obesity group (p = 0.02). ICAM1 mRNA level tended to be higher in 
obesity group compared to non-obesity group, but it did not reach a significant difference. Similarly, we compared 
expression levels of various factors between obesity and non-obesity group in the media. As shown in Fig. 2B, 
GLP-1 receptor and TCF7L2 mRNA levels in the media were significantly lower in obesity group compared to 
non-obesity group (p < 0.01 and p = 0.02, respectively) which was also consistent with the immunostaining data. 
In contrast, PAI-1 mRNA level in obesity group tended to be higher than that in non-obesity group. It is noted 
here that although it is known that TCF7L2 functions as a transcriptional factor of GLP-1 receptor gene in pan-
creatic β-cells20, it is not thought that ICAM1 and PAI-1 are the downstream of TCF7L2.
TCF7L2 is a possible regulator of GLP-1 receptor expression in human vascular cells. Since there 
was correlation between the expression levels of GLP-1 receptor and TCF7L2 in the aorta in our experiments and 
it is well known that TCF7L2 is a transcriptional factor of GLP-1 receptor in pancreatic β-cells, we hypothesized 
that TCF7L2 regulates GLP-1 receptor expression in human vascular cells as observed in β-cells. To demonstrate 
this hypothesis, we exposed human umbilical vein endothelial cells (HUVEC) and human aortic endothelial cells 
Obese (n = 16)
(BMI ≥ 25 kg/m2)
Non-obese (n = 24)
(BMI < 25 kg/m2) p
Arterial dissection/Aneurysm/ ASO/
Amputation/etc. 11/5/0/0/0 9/7/6/1/1
Diabetes/Non-diabetes 5/11 (31.3%) 6/17 (26.1%) n.s.
With hypertension 5 (31.3%) 7 (29.2%) n.s.
With ARB or ACE-I 4 (25.0%) 3 (12.5%) n.s.
With Ca-blockers 3 (18.8%) 4 (16.7%) n.s.
With dyslipidemia 13 (81.3%) 19 (79.2%) n.s.
With statin 3 (18.8%) 8 (33.3%) n.s.
With anti-coagulant drugs 0 (0%) 4 (16.7%) 0.036
Age 61.4 ± 16.7 72.1 ± 9.1 0.047
BMI (kg/m2) 28.6 ± 2.5 20.7 ± 2.8 <0.0001
HbA1c (%) 5.9 ± 0.6 6.4 ± 1.9 n.s.
Fasting plasma glucose (mg/dl) 121.2 ± 32.2 116.6 ± 25.0 n.s.
LDL cholesterol (mg/dl) 111.1 ± 38.1 91.3 ± 33.0 n.s.
HDL cholesterol (mg/dl) 37.1 ± 10.3 39.0 ± 9.0 n.s.
C-reactive protein (mg/dl) 2.3 ± 1.0 1.9 ± 0.6 n.s.
Table 1. Patient background-Obese and non-obese subjects-. Abbreviations: ARB, angiotensin II receptor 
blocker; ACE-I, angiotensin converting enzyme inhibitor; ASO, arteriosclerosis obliterans; BMI, body mass 
index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; n.s. not significant.
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(HAEC) to siRNA directed to TCF7L2 (siTCF7L2) or scrambled control siRNA and cultured them for 24 hours. 
Both in HUVEC (Fig. 3A) and HAEC (Fig. 3B), siTCF7L2 significantly reduced TCF7L2 mRNA levels compared 
to control, and such reduction of TCF7L2 led to the significant down-regulation of GLP-1 receptor mRNA expres-
sion level, respectively (p = 0.0005, p = 0.0024). Since it is important to know that protein levels of TCF7L2 and 
GLP-1 receptor are also altered after the change of their mRNA levels, we performed western blotting to confirm 
this point. As shown in (Fig. 3C,D), both in HUVEC (Fig. 3C) and HAEC (Fig. 3D), siTCF7L2 decreased TCF7L2 
protein levels compared with control and such reduction of TCF7L2 led to the significant down-regulation of 
Figure 1. (A) Comparison of vascular GLP-1 receptor expression between non-obese (upper panels) and obese 
human subjects (middle panels). Double staining for GLP-1 receptor in green, DAPI in blue in human artery 
sections. Lower panels show immunostaining for GLP-1 receptor without the GLP-1 receptor antibody. (B) 
Comparison of vascular TCF7L2 expression between non-obese and obese human subjects. Triple staining for 
TCF7L2 in green, intima in red with CD34 antibody, DAPI in blue in human artery sections.
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GLP-1 receptor protein expressions, respectively (p = 0.005, p = 0.002). Furthermore, in order to strengthen our 
hypothesis, we conducted the TCF7L2 overexpression study using TCF7L2-EGFP expressing adenovirus24. We 
exposed HAEC to TCF7L2-EGFP adenovirus or control EGFP and cultured them for 48 hours. As expected, 
TCF7L2-EGFP expression was largely confined to the nucleoplasm (Fig. 4A). As shown in Fig. 4B, TCF7L2-EGFP 
adenovirus significantly increased TCF7L2 mRNA levels compared with control and such increment of TCF7L2 
led to the significant up-regulation of GLP-1 receptor expressions (p < 0.05). A similar phenomenon was proved 
even with protein; TCF7L2-EGFP adenovirus significantly increased TCF7L2 and GLP-1 receptor protein expres-
sion levels as well (Fig. 4C, p = 0.04).
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Body mass index (BMI) is an independent determining factor of GLP-1 receptor expression 
both in the intima and media of aorta in human subjects. Next, to examine which factors are asso-
ciated with GLP-1 receptor expression in human aorta, we performed univariate analyses. As shown in Table 2, 
there was significantly negative correlation between GLP-1 receptor gene expression and BMI, LDL-cholesterol 
in the intima (p < 0.01 and p = 0.02, respectively) and media (p < 0.001 and p = 0.04, respectively). Furthermore, 
to examine which factors independently determine GLP-1 receptor expression in the intima and media, we per-
formed multivariate analyses. As shown in Table 2, only BMI had a significant negative correlation with GLP-1 
receptor gene expression in the intima and media (p = 0.03 and p < 0.001, respectively).
We examined the possible correlation of GLP-1 receptor and TCF7L2 mRNA levels with the type of arterial 
pathology observed. However, there was no clear correlation between them. In addition, we compared GLP-1 
expression between subjects with and without various diseases or medication. However, between the subjects 
with and without hypertension (p = 0.16 and p = 0.52, respectively), dyslipidemia (p = 0.51 and p = 0.42, respec-
tively) or diabetes (p = 0.88 and p = 0.68, respectively), there were no significant differences in GLP-1 receptor 
expression in intima and media, respectively. There were no significant difference in GLP-1 receptor expres-
sion in intima and media between the subjects with and without ARB (p = 0.83 and p = 0.75, respectively) or 
anti-diabetic drugs (p = 0.70 and p = 0.20, respectively). Also, there was no difference in GLP-1 receptor expres-
sion between young and senior subjects (p = 0.14 and p = 0.17, respectively) (≥65 years old) and between subjects 
with and without urinary albumin (p = 0.55 and p = 0.37, respectively) (≥30 mg/gCr).
Discussion
It has been reported so far that incretin plays pleiotropic roles in various kinds of tissues and many scientists all over 
the world have been performing a variety of experiments to elucidate the importance of incretin signaling. In such 
a situation, one of the largest obstacles is that most of the GLP-1 receptor antibodies which are available now are 
not working very well in several experiments including immunostaining and western blotting. It has been drawing 
attention, however, GLP-1 receptor antibody MAb 3F52 which was developed by Novonordisk Pharma has been 
working very well22. Indeed, various studies using this excellent antibody has showed the localization of GLP-1 
receptor and novel findings in primates one after another. It is no exaggeration to say that the appearance of the anti-
body has repainted the conventional idea. This excellent antibody was working very well in this study as reported22 
and thereby enabled us to start performing this research and to demonstrate the new findings in human subjects.
In the present study, we demonstrated GLP-1 receptor expression in human artery was down-regulated in 
subjects with obesity and/or hypercholesterolemia. Generally, obese subjects tend to have higher frequency to 
cause macroangiopathy compared to non-obese subjects. Therefore, we think that declining of GLP-1 recep-
tor expression in aorta in obese subjects may be involved in such high frequency of macrovascular complica-
tions. It has been thought that vascular GLP-1 signaling acts as anti-arteriosclerotic effects. But there was no 
report showing the factors that contribute to GLP-1 receptor expression in human artery. To the best of our 
knowledge, this is the first report demonstrating that GLP-1 receptor expression decreases in the aorta of 
obese human subjects. It was reported that GLP-1 receptor expression in pancreatic β-cells was suppressed by 
gluco-lopotoxicity18,19. Considered from the data in this study, lipotoxicity rather than hyperglycemia is likely 
related to the reduced expression of GLP-1 receptor in aorta, although it is necessary to perform further study 
in order to strengthen our hypothesis. It seems that there is some difference between acute and chronic effects of 
increased glucose and/or cholesterol levels on GLP-1 receptor expression levels. Since it was practically difficult to 
culture HUVEC for a long period, we cultured HUVEC for 3–5 days under increased glucose and/or cholesterol 
Clinical parameter
Univariate analysis Multivariate analysis
ρ p β p
Vascular intima
Age 0.14 n.s. −0.14 n.s.
Gender −0.06 n.s. 0.08 n.s.
BMI −0.41 <0.01 −0.40 <0.05
HbA1c −0.14 n.s.
Fasting plasma glucose 0.02 n.s.
LDL cholesterol −0.37 <0.05 −0.24 n.s.
HDL cholesterol −0.10 n.s.
Vascular media
Age 0.20 n.s. −0.02 n.s.
Gender −0.16 n.s. 0.13 n.s.
BMI −0.55 <0.001 −0.56 <0.001
HbA1c 0.00 n.s.
Fasting plasma glucose 0.32 n.s.
LDL cholesterol −0.32 <0.05 −0.14 n.s.
HDL cholesterol 0.02 n.s.
Table 2. The independent factor which contributes to GLP-1 receptor expression. Abbreviations: BMI, body 
mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; n.s. not significant.
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levels and then evaluated GLP-1 receptor expression levels. As the results, interestingly, GLP-1 receptor expres-
sion was not decreased at all after acute exposure to increased glucose and/or cholesterol levels (Supplemental 
Fig. 1). However, as shown in this study, GLP-1 receptor expression was significantly decreased in obese subjects. 
Therefore, we assume that there is some large difference between acute and chronic effects of increased glucose 
and/or cholesterol levels on GLP-1 receptor expression levels. Indeed, it is well known that there is large difference 
between acute and chronic effects of various stimuli on some phenomena. For example, acute exposure to high 
glucose concentration increases GIP receptor expression in pancreatic β-cells whereas chronic exposure to high 
glucose concentration reduces GIP receptor in β-cells19. Although speculative, we assume that after short expo-
sure of artery to hyperglycemia and/or hypercholesterolemia, GLP-1 receptor increases to protect artery initially, 
but that after chronic exposure to them, such protective pathway does not appropriately function. In addition, it 
was strongly suggested that TCF7L2 is the modulator of GLP-1 receptor in human endothelial cells as observed in 
β-cells20. It was reported that TCF7L2 plays a cell autonomous role in the control of pancreatic β-cell function and 
mass25. We made TCF7L2 expressing adenovirus24 and confirmed that TCF7L2 overexpression increased GLP-1 
receptor expression in arterial cells. These data showed the possible coordination between TCF7L2 and GLP-1 
receptor in arterial cells. In addition, since TCF7L2 is a transcription factor, we think that TCF7L2 trans-activates 
GLP-1 receptor gene in cell autonomous manner. It has been reported that GLP-1 plays protective role on the 
progression of atherosclerosis. Therefore, we think the preservation of TCF7L2 level in the arterial cells would be 
very important for the prevention and/or protection of atherosclerosis.
As shown in Table 2, both BMI and LDL cholesterol were associated with GLP-1 receptor expression in uni-
variate analysis, but in multivariate analysis BMI alone was significant determinant factor for GLP-1 receptor 
expression level and LDL cholesterol became non-significant for it. Since there could be some co-linearrity 
between BMI and LDL cholesterol in several cases, we think that the non-significance of LDL cholesterol in mul-
tivariate analysis might have been due to such possible co-linearity between them.
In addition, it was previously reported that GLP-1 signaling activates endothelial nitric oxide synthase (eNOS) 
and reduces reactive oxygen species (ROS) which finally leads to reduce inflammatory process and the pro-
gression of atherosclerosis. Therefore, we assume that the decreased expression of arterial GLP-1 receptor in 
obese subjects would lead to the inactivation of eNOS and increase of ROS. We also think that such decreased 
GLP-1 receptor expression could explain, at least partially, the mechanism by which atherosclerosis is facili-
tated in obsess subjects. In addition, at present there was no report demonstrating that TCF7L2 per se had an 
anti-inflammatory effect. However, if it is demonstrated that TCF7L2 has some anti-inflammatory effects, GLP-1 
receptor could be a crucial down-stream event for TCF7L2-mediated anti-inflammatory effects. Therefore, it is 
possible that preservation of TCF7L2 expression could lead to reduce the atherosclerosis through the increase of 
GLP-1 receptor expression and decrease of inflammation process, although further evaluation would be neces-
sary to demonstrate this point.
There is a limitation in this study. Because it is very difficult to obtain arteries in subjects who do not need 
surgical operation, we performed various experiments using large and small arteries in subjects with some 
vascular diseases which need surgical operation. Therefore, we cannot exclude the possibility that the data in 
this study were partially influenced by the presence of such vascular diseases. In addition, it would be better 
to perform western blotting rather than immunohistochemistry in order to perform quantitatively evaluation. 
Although we performed western blotting and the convincing data in HUVEC and HAEC experiments, we failed 
to obtain the patient samples for western blotting because many patients in this study needed emergency oper-
ation. Next, it would be much better to show some metabolic parameters involved in regulating arterial GLP-1 
receptor and TCF7L2 levels. Since it has been reported that GLP-1 receptor expression level in pancreatic β-cells 
is down-regulated by lipotoxicity such as free fatty acids (FFA) and/or triglyceride (TG) both of which are usually 
high in obese subjects, we assume that FFA and TG are possible parameters involved in arterial GLP-1 receptor 
and TCL7L2 levels. On the other hands, it is well known that there is marked difference between before and 
after meal in such parameter levels. Since many patients in this study needed emergency operation, we failed to 
obtain such parameters in fasting status. In addition, since many patients needed intravenous drip injection after 
the emergency operation, FFA and TG levels were markedly affected by such injection. In the present study, we 
showed that GLP-1 receptor was present in the intima and media and that its expression level was lower in obese 
subjects. However, it is known that GLP-1 receptor is present in various tissues in vessels such as macrophages 
and monocytes. In addition, it has been drawing attention that GLP-1 acts on GLP-1 receptor in atrium which 
contributes to the relaxation of blood vessels. Therefore, it remains unclear which GLP-1 receptor expression is 
most important for such relaxation of blood vessels among GLP-1 receptor expression in various kinds of cells.
Taken together, we think that the findings in the present study using vascular cells in human subjects would 
provide marvelous information and have great significance not only from the clinical point of view but also in 
vascular biology research area, because very recently anti-arteriosclerotic effects through GLP-1 receptor were 
demonstrated in clinical human study in addition to basic study. Since it was shown that administration of GLP-1 
receptor agonist in subjects with type 2 diabetes resulted in reduction of cardiovascular-related events and/or 
death17, the role of GLP-1 receptor in vascular cells has been drawing much more attention in clinicians as well 
as researchers. In such circumstances, we believe that the decrement of vascular GLP-1 receptor expression is 
involved in the progression of arteriosclerosis and the onset of cardiovascular events. In addition, the data in this 
study suggest the possibility that incretin-related drugs such as GLP-1 receptor agonist would exert more protec-
tive effects on arteries in non-obese subjects and that amelioration of obesity would be beneficial to augment the 
protective effects of such drugs on arteries although further evaluation such as prospective clinical study would 
be necessary to demonstrate these points.
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